Performance of Serum CA125 as a Prognostic Biomarker in Patients With Uterine Papillary Serous Carcinoma
- 1 April 2011
- journal article
- research article
- Published by BMJ in International Journal of Gynecologic Cancer
- Vol. 21 (3), 529-534
- https://doi.org/10.1097/igc.0b013e31821091b5
Abstract
Hypothesis: Serum CA125 is a potential biomarker for metastatic disease and recurrence in patients with uterine papillary serous carcinoma (UPSC).Methods: All patients with UPSC who had preoperative CA125 measurement and surgical staging between 1998 and 2008 at the participating institutions were included in this analysis (N = 52). Data were extracted from patients' records. Fisher exact and χ2tests were used to assess the association of CA125 levels with clinical and pathological variables. The correlation between CA125 levels (high/low) and lymph node metastases (positive/negative) was evaluated using Spearman correlation coefficients. The association of CA125 elevation with recurrence-free survival was assessed using Cox proportional hazards regression modeling.Results: Preoperative CA125 elevation (>30 U/mL) was observed in 9 (17%) patients and was associated with advanced International Federation of Gynecologists and Obstetricians (FIGO) stage III/IV disease (P= 0.002), lymph node involvement (P= 0.007), and presence of omental metastases (P= 0.001). Disease recurrence and survival data were available for 51 of the 52 patients. During a mean follow-up time of 36 months, 15 (29%) patients experienced disease recurrence and 10 (19%) patients died. There was a moderate positive correlation between CA125 levels and lymph node metastases (r2= 0.39). On multivariate survival analysis, an elevated CA125 level compared to nonelevated CA-125 was not associated with disease recurrence (hazard ratio, 1.61; 95% confidence interval, 0.55-4.77).Conclusions: Preoperative CA125 levels were significantly associated with metastatic disease in patients with UPSC. However, in this study of surgically staged UPSC patients, preoperative CA125 elevation was not an independent predictor of disease recurrence.Keywords
This publication has 24 references indexed in Scilit:
- Minimal uterine serous carcinoma: a clinicopathological study of 40 casesLaboratory Investigation, 2005
- Uterine papillary serous carcinoma (UPSC): a single institution review of 129 casesGynecologic Oncology, 2003
- Extended Surgical Staging for Uterine Papillary Serous Carcinoma: Survival Outcome of Locoregional (Stage I–III) DiseaseGynecologic Oncology, 2001
- Noninvasive papillary serous carcinoma of the endometriumPublished by Ovid Technologies (Wolters Kluwer Health) ,2001
- Minimal Uterine Serous CarcinomaThe American Journal of Surgical Pathology, 2000
- The Outcome of Stage I–II Clinically and Surgically Staged Papillary Serous and Clear Cell Endometrial Cancers When Compared with Endometrioid CarcinomaGynecologic Oncology, 2000
- Uterine Papillary Serous Carcinoma (UPSC): A Clinicopathologic Study of 30 CasesGynecologic Oncology, 1995
- Uterine Papillary Serous Carcinoma: Patterns of Metastatic SpreadGynecologic Oncology, 1994
- Uterine Serous Carcinoma A Morphologically Diverse Neoplasm With Unifying Clinicopathologic FeaturesThe American Journal of Surgical Pathology, 1992
- Adenocarcinoma of the endometrium: Analysis of 256 cases with carcinoma limited to the uterine corpus: Pathology review and analysis of prognostic variablesGynecologic Oncology, 1982